167 related articles for article (PubMed ID: 37082801)
21. Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens.
Doxtader EE; Mukhopadhyay S
Cancer Cytopathol; 2018 Apr; 126(4):243-252. PubMed ID: 29360191
[TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
23. Expression of neuroendocrine markers predicts increased survival in triple-negative breast cancer patients.
Xia C; Shen S; Pang J; Chen L; Yan J; Liang Z; Ren X
Front Endocrinol (Lausanne); 2023; 14():1205631. PubMed ID: 38125789
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: involvement of the RB-microRNA axis.
Liu X; Gu X; Sun L; Flowers AB; Rademaker AW; Zhou Y; Kiyokawa H
BMC Cancer; 2014 Feb; 14():57. PubMed ID: 24485087
[TBL] [Abstract][Full Text] [Related]
25. INSM1 expression in primary and metastatic neuroendocrine neoplasms at distinct locations.
Wang XQ; Fu J; Zhang YT; Xu Y
Pathol Res Pract; 2024 Jan; 253():155067. PubMed ID: 38171081
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center.
Shafi S; Hu Y; Parwani AV; Ding Q; Li Z
Breast Cancer Res Treat; 2022 Dec; 196(3):463-469. PubMed ID: 36260193
[TBL] [Abstract][Full Text] [Related]
27. Application of INSM1 in Diagnosis and Grading of Laryngeal Neuroendocrine Carcinoma.
Yuan C; Jiao F; Zhai C; Zhang J; Wang S; Zhu L
Laryngoscope; 2021 Oct; 131(10):E2662-E2668. PubMed ID: 33847383
[TBL] [Abstract][Full Text] [Related]
28. Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors.
Sugianto J; Sarode V; Peng Y
Hum Pathol; 2014 Apr; 45(4):802-9. PubMed ID: 24560018
[TBL] [Abstract][Full Text] [Related]
29. Exploration of INSM1 and hASH1 as additional markers in lung cytology samples of high-grade neuroendocrine carcinoma with indeterminate neuroendocrine differentiation.
Rothrock AT; Stewart J; Li F; Racila E; Amin K
Diagn Cytopathol; 2022 May; 50(5):230-234. PubMed ID: 35147301
[TBL] [Abstract][Full Text] [Related]
30. A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases.
Kuji S; Watanabe R; Sato Y; Iwata T; Hirashima Y; Takekuma M; Ito I; Abe M; Nagashio R; Omae K; Aoki D; Kameya T
Gynecol Oncol; 2017 Feb; 144(2):384-390. PubMed ID: 27908529
[TBL] [Abstract][Full Text] [Related]
31. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
[TBL] [Abstract][Full Text] [Related]
32. Expression of p53 and Rb reveal subtypes of gastric neuroendocrine carcinoma with distinct prognosis.
Xing J; Chen J; You T; Sun Z; Lu T; Cheng Y; Wu H; Bai C
J Neuroendocrinol; 2023 Apr; 35(4):e13257. PubMed ID: 36964649
[TBL] [Abstract][Full Text] [Related]
33. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
34. INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity.
Rooper LM; Sharma R; Li QK; Illei PB; Westra WH
Am J Surg Pathol; 2017 Nov; 41(11):1561-1569. PubMed ID: 28719469
[TBL] [Abstract][Full Text] [Related]
35. INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors.
Rooper LM; Bishop JA; Westra WH
Am J Surg Pathol; 2018 May; 42(5):665-671. PubMed ID: 29438167
[TBL] [Abstract][Full Text] [Related]
36. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
[TBL] [Abstract][Full Text] [Related]
37. INSM1 Is Less Sensitive But More Specific Than Synaptophysin in Gynecologic High-grade Neuroendocrine Carcinomas: An Immunohistochemical Study of 75 Cases With Specificity Test and Literature Review.
Zou Q; Zhang L; Cheng Z; Guo X; Cao D
Am J Surg Pathol; 2021 Feb; 45(2):147-159. PubMed ID: 33264139
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous Neuroendocrine Mucinous Carcinomas Are Low-grade But May Be Associated With Other Cancers.
Adkins KE; Busam K; Pulitzer M
Am J Surg Pathol; 2023 Oct; 47(10):1186-1191. PubMed ID: 37530225
[TBL] [Abstract][Full Text] [Related]
39. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
Shamir ER; Devine WP; Pekmezci M; Umetsu SE; Krings G; Federman S; Cho SJ; Saunders TA; Jen KY; Bergsland E; Jones K; Kim GE; Kakar S; Chiu CY; Joseph NM
Mod Pathol; 2019 Feb; 32(2):290-305. PubMed ID: 30237525
[TBL] [Abstract][Full Text] [Related]
40. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]